Physician profile
Mark E Clement
NPI 1780666966
$11,047.47
in general payments reported to CMS, 2019-2025
19 companies · $595 in 2025
The $595 reported for 2025 was more than what 81% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,431 · 2020: $540 · 2021: $366 · 2022: $5,006 · 2023: $1,122 · 2024: $989 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,705.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $7,387.22 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Bausch & Lomb Americas INC. | $851.19 | 2023-2025 | Miebo, Xiidra, Infuse |
| Novartis Pharmaceuticals Corporation | $458.11 | 2019-2023 | |
| Alcon Vision LLC | $410.98 | 2019-2024 | Total30, Precision 1, Dailies Total1 |
| Allergan, INC. | $281.83 | 2020-2022 | |
| Lkc Technologies, INC. | $269.37 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $262.38 | 2021-2024 | Cequa |
| Optovue, INC. | $138.12 | 2019-2020 | |
| Johnson & Johnson Vision Care, INC. | $127.97 | 2019-2024 | |
| Oyster Point Pharma, INC. | $126.65 | 2022-2024 | Tyrvaya |
| Abbvie INC. | $121.91 | 2022 | |
| Horizon Therapeutics Plc | $120.79 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $118.53 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $112.89 | 2022 | |
| Topcon Healthcare, INC. | $90.43 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $64.65 | 2019 | |
| Biotissue Holdings INC. | $60.20 | 2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $28.37 | 2019-2021 | |
| Astellas Pharma US INC | $15.88 | 2025 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Clement listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.